Immune-Mediated Inflammatory Diseases (IMID) Treatment Market to Reach $191.04 Billion by 2035

Immune-mediated inflammatory disease (IMID) treatment market was valued at $121.0 billion in 2025 and is projected to reach $191.04 billion by 2035, growing at a CAGR of 4.67% during the forecast period (2026–2035). The rising global burden of chronic inflammatory and autoimmune diseases, coupled with increased adoption of biologics and targeted therapies, is significantly driving market expansion. Governments and healthcare systems are increasingly prioritizing early diagnosis and long-term disease management to reduce disability and healthcare costs associated with IMIDs. Advanced biologics and targeted synthetic DMARDs are playing a critical role in improving patient outcomes by offering higher efficacy, reduced disease progression, and personalized treatment approaches.

Browse the full report description of “Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Size, Share & Trends Analysis Report, By Drug Class (Biologics, Targeted Synthetic DMARDs, Conventional DMARDs, Corticosteroids, NSAIDs), By Disease Type (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Inflammatory Bowel Disease (IBD), Ankylosing Spondylitis (AS), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS), Others), By Treatment Type (Targeted Biologic Therapies, Novel Therapies), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/immune-mediated-inflammatory-diseases-treatment-market

Biologics remain the dominant drug class due to their strong clinical effectiveness in managing diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Meanwhile, targeted synthetic DMARDs are gaining rapid traction owing to their oral administration and precision targeting mechanisms. The increasing prevalence of autoimmune diseases, combined with improved access to specialty drugs and expanding reimbursement frameworks, continues to support sustained market growth across developed and emerging economies.

Rising Global Burden of Autoimmune Diseases Driving Treatment Demand

According to the World Health Organization, autoimmune diseases are among the leading causes of morbidity globally, affecting approximately 5–8% of the global population. In addition, data from the Centers for Disease Control and Prevention indicates that 8% people in the United States are currently living with autoimmune conditions, with prevalence steadily increasing due to improved diagnostic capabilities and environmental factors.

This growing disease burden is directly accelerating demand for advanced IMID therapies. Chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel disease require long-term treatment, creating sustained demand for biologics and targeted therapies. Governments are also investing in early intervention programs and awareness campaigns to reduce disease progression and improve quality of life, further strengthening the treatment landscape.

Biologic Innovation and Precision Medicine Accelerating Market Growth

The increasing focus on biologic innovation and precision medicine is transforming the IMID treatment market. Regulatory bodies such as the U.S. Food and Drug Administration and the European Medicines Agency have accelerated approvals for novel biologics and biosimilars between 2023 and 2026, improving patient access and fostering competition.

For instance, in May 2023, . These developments highlight a strategic shift toward personalized, data-driven approaches to improve clinical outcomes and redefine standards of care in IMID therapies.

Innovation Leaders Empowering the IMID Treatment Market

Key players in the IMID treatment market include AbbVie Inc., Johnson & Johnson, Sanofi S.A., Novartis AG, and Roche (Genentech), among others. These companies are driving innovation through the development of biologics, biosimilars, and targeted synthetic therapies, focusing on improved efficacy, safety profiles, and patient-centric treatment approaches.

• In September 2025, Johnson & Johnson continued its innovation in inflammatory bowel disease (IBD) therapies. The company recently secured FDA approval for a novel dual-acting monoclonal antibody targeting both ulcerative colitis and Crohn’s disease, demonstrating improved clinical outcomes and intestinal healing. These developments underscore the industry’s shift toward more targeted, biologic-driven therapies to address complex IMID conditions.
• In December 2023, Sanofi strengthened its position in the Immune-Mediated Inflammatory Diseases (IMID) market by advancing a robust immunology-focused pipeline featuring 12 potential blockbuster assets. The company is prioritizing multi-indication therapies such as amlitelimab and frexalimab to address unmet patient needs and expand treatment applications.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  o By Drug Class
  o By Disease Type
  o By Treatment Type
  o Competitive Landscape – AbbVie Inc., Johnson & Johnson, Sanofi S.A., Novartis AG, Roche (Genentech), among others

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Report Segment

By Drug Class

• Biologics
• Targeted Synthetic DMARDs (tsDMARDs)
• Conventional DMARDs (csDMARDs)
• Corticosteroids
• NSAIDs

By Disease Type

• Rheumatoid Arthritis (RA)
• Psoriasis
• Psoriatic Arthritis (PsA)
• Inflammatory Bowel Disease (IBD)
• Ankylosing Spondylitis (AS)
• Systemic Lupus Erythematosus (SLE)
• Multiple Sclerosis (MS)
• Others

By Treatment Type

• Targeted Biologic Therapies
• Novel Therapies

Global Immune-Mediated Inflammatory Diseases (IMID) Treatment Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/immune-mediated-inflammatory-diseases-treatment-market